Cargando…
Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
Recently developed potent and selective CDK4/6 inhibitors fall into two classes based on structure and toxicity profiles in clinical studies. One class, exemplified by palbociclib and ribociclib, exhibits neutropenia as a dose-limiting toxicity and requires discontinuous dosing. In contrast, the str...
Autores principales: | Knudsen, Erik S., Hutcheson, Jack, Vail, Paris, Witkiewicz, Agnieszka K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546433/ https://www.ncbi.nlm.nih.gov/pubmed/28620137 http://dx.doi.org/10.18632/oncotarget.18435 |
Ejemplares similares
-
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer
por: Knudsen, Erik S., et al.
Publicado: (2016) -
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2015) -
The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017) -
Determinants of response to CDK4/6 inhibitors in the real-world setting
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2023) -
The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)